May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Results of a Phase I Study of Intravitreal VEGF Trap in Subjects With Diabetic Macular Edema: The CLEAR-IT DME Study
Author Affiliations & Notes
  • D. V. Do
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Q. D. Nguyen
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • D. J. Browning
    Charlotte Eye Ear Nose & Throat, PA, Charlotte, North Carolina
  • J. A. Haller
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • K. Chu
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York
  • J. Buskey
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York
  • I. Grimes
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York
  • A. Ingerman
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York
  • J. Cederbaum
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York
  • P. A. Campochiaro
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Footnotes
    Commercial Relationships D.V. Do, None; Q.D. Nguyen, None; D.J. Browning, None; J.A. Haller, None; K. Chu, Regeneron Pharmaceuticals, Inc, E; J. Buskey, Regeneron Pharmaceuticals, Inc, E; I. Grimes, Regeneron Pharmaceuticals, Inc, E; A. Ingerman, Regeneron Pharmaceuticals, Inc, E; J. Cederbaum, Regeneron Pharmaceuticals, Inc, E; P.A. Campochiaro, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1430. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. V. Do, Q. D. Nguyen, D. J. Browning, J. A. Haller, K. Chu, J. Buskey, I. Grimes, A. Ingerman, J. Cederbaum, P. A. Campochiaro; Results of a Phase I Study of Intravitreal VEGF Trap in Subjects With Diabetic Macular Edema: The CLEAR-IT DME Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1430. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To determine the safety, tolerability, and bioactivity of a single dose (4.0mg) of intravitreal VEGF Trap in patients with diabetic macular edema (DME).

Methods:: Five patients with DME, foveal thickness ≥ 250µm measured by optical coherence tomography (OCT) and ETDRS best-corrected visual acuity (BCVA) of ≤ 20/40 and ≥ 20/320 were administered a single intravitreal injection of 4 mg VEGF Trap at day 0. Safety assessments included eye examinations, vital signs, and laboratory tests. Measures of bioactivity included changes from baseline in BCVA, centerpoint retinal thickness (CRT), and leakage on fluorescein angiography. Subjects were monitored for 6 weeks following VEGF Trap administration.

Results:: Mean patient age was 65.2 years (range=56-75); 4 were Type 2 diabetics. Mean duration of diabetes prior to treatment was 26 years. All had received prior treatment for DME. No severe ocular or serious systemic adverse events related to study drug were noted. Mean baseline BCVA was 69 letters and mean baseline CRT was 407µm. Four patients had improvements in BCVA, ranging from 6 to 10 letters at 4 weeks post-injection. The mean decrease in centerpoint retinal thickness was 115µm at 4 weeks.

Conclusions:: A single intravitreal dose of VEGF Trap was well-tolerated and led to a reduction in CRT and an improvement in BCVA. Although the number of subjects is small, preliminary evidence for bioactivity of VEGF Trap in patients with DME was detected. Additional studies are being planned to identify the potential therapeutic role of intravitreal VEGF Trap in DME.

Clinical Trial:: www.clinicaltrials.gov NCT 00320814

Keywords: diabetic retinopathy • macula/fovea • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×